KRON - Kronos Bio, Inc. Growth-Adjusted Payback Ratio

The high scientific expertise of Kronos Bio, Inc. (KRON) leadership is currently facing the necessity of stringent cost reductions and a comprehensive review of the development portfolio. The PEG growth stock indicator reflects the current market valuation, where the value has stabilized at 0.00. The company's prospects rely on the success of SYK inhibitors and the validation of their therapeutic platform's efficacy in treating tumors.

KRON Kronos Bio Corporation Price/Earnings to Growth Ratio (07/04/2022 - 06/28/2025)

Metric breakdowns and analytics for Kronos Bio, Inc. (KRON)

- current price and projected stock value:

Price Chart Kronos Bio Inc|KRON - Consensus Target

- market capitalization statistics:

Market Value Kronos Bio Corp|KRON - Total Company Value

- book capitalization indicators:

Net Asset Value per Share Kronos Bio|KRON - Company Book Value|Capitalization to Book Value Ratio kronosbio.com|KRON - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

KRON - Net Income|Expected Net Profit Kronos Bio, Inc.|KRON - Price to Earnings Ratio|Future Price to Earnings Multiple Kronos Bio Corporation|KRON - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Kronos Bio Corp|KRON - Operating profit EBITDA|Earnings per share for the trailing year Kronos Bio|KRON - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months kronosbio.com|KRON - Earnings per share growth in current year|Expected earnings per share trend next year Kronos Bio, Inc.

Fundamental company analysis:Kronos Bio Inc KRON

For Kronos Bio, Inc. (KRON), a disciplined developer of targeted oncology drugs, the undervalued "rockets" filter based on PEG visualizes the balance between market valuation and profit expansion rates. This indicator adjusts the classic P/E ratio for the expected business growth rate: a value below one signals that the asset is undervalued, confirming the attractiveness of the capital while maintaining the brand's scientific expertise in transcription.

Competitors of Kronos Bio, Inc.